Form 4: Neumora Therapeutics Executive Sells Shares to Cover Tax Obligations

Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold 5,614 shares of common stock on February 18, 2025, to cover withholding obligations related to vesting restricted stock units.

Summary

• Robert A. Lenz, Head of R&D at Neumora Therapeutics, sold 5,614 shares of common stock on February 18, 2025.
• The sale was executed at a weighted average price of $1.6714 per share, with individual trades ranging from $1.66 to $1.695.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2024.
• The purpose of the sale was to satisfy withholding tax obligations associated with the vesting of restricted stock units.
• Following the transaction, Lenz directly owns 309,092 shares of Neumora Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (stock sale for tax obligations) by an executive, which is neither particularly positive nor negative from an investment perspective.

Industry Context

Sales of shares by company insiders are a normal part of executive compensation, especially when tied to vesting events. These sales are often pre-planned using 10b5-1 trading plans to avoid accusations of insider trading. The market typically views these sales as routine unless the size or frequency is unusual.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• It is standard practice for executives to sell a portion of these shares upon vesting to cover income tax obligations.
• Rule 10b5-1 trading plans are a common tool used by corporate insiders to manage these transactions in compliance with securities laws.
• Comparable companies such as Biogen, Eli Lilly, and Pfizer also see regular insider transactions related to equity compensation.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to significantly affect long-term shareholder value.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Neumora Therapeutics, NMRA, Robert A. Lenz, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Executive Compensation, Head of R&D